PODD Sep 2023 360.000 call
| Previous close | 5.50 |
| Open | 6.20 |
| Bid | 0.00 |
| Ask | 2.60 |
| Strike | 360.00 |
| Expiry date | 2023-09-15 |
| Day's range | 5.50 - 6.20 |
| Contract range | N/A |
| Volume | |
| Open interest | 49 |
ZacksHere's Why You Should Retain Insulet (PODD) Stock for Now
Investors continue to be optimistic about Insulet (PODD) on the robust performance of Omnipod 5.
ZacksHAE or PODD: Which Is the Better Value Stock Right Now?
HAE vs. PODD: Which Stock Is the Better Value Option?
Simply Wall St.Insulet (NASDAQ:PODD) shareholder returns have been splendid, earning 271% in 5 years
When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...
ZacksZacks.com featured highlights include Franklin Electric, Insulet and Wingstop
Franklin Electric, Insulet and Wingstop are part of the Zacks Screen of the Week article.
ZacksAbbott (ABT) EPD Business Grows Strong, Macro Issues Stay
Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business.
ZacksZacks Industry Outlook Highlights Stryker, Boston Scientific, Zimmer Biomet and Insulet
Stryker, Boston Scientific, Zimmer Biomet and Insulet are part of the Zacks Industry Outlook article.
ZacksHere's Why Investors Should Retain Syneos Health (SYNH) for Now
Syneos Health's (SYNH) share price movement is expected to be favorable due to the strength of the company's Syneos One portfolio and several value-added partnership deals.
ZacksInsulet (PODD) Q1 Earnings Beat Estimates, Sales View Up
Omnipod 5 continues to be a driving force of Insulet's (PODD) strong U.S. growth, representing almost 95% of U.S. new customer starts in the first quarter.
Zacks4 Medical Products Stocks to Capitalize on the Industry's Recovery
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. SYK, BSX, ZBH and PODD are well-poised to gain from the favorable factors.
ZacksInsulet (PODD) Q1 Earnings and Revenues Top Estimates
Insulet (PODD) delivered earnings and revenue surprises of 155.56% and 8.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireInsulet Announces New Organizational Structure to Drive Further Growth
ACTON, Mass., May 04, 2023--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its new organizational structure designed to accelerate innovation and commercialization. The new structure will be implemented during the second half of this year with new leadership roles effective July 1, 2023. The leadership team will continue to report to Jim Hollingshead, President and Chief Execu
Business WireInsulet Reports First Quarter 2023 Revenue Increase of 21% Year-Over-Year (23% Constant Currency1)
ACTON, Mass., May 04, 2023--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2023.
ZacksBuy These 5 Stocks Ahead of Earnings Releases This Week
We have narrowed our search to five stocks that are set to report earnings results this week. These are: PODD, BKNG, BILL, JCI and COLD.
Business WireInsulet Publishes 2022 Sustainability Report Focused on Innovating for the Future and Preserving the Environment
ACTON, Mass., May 02, 2023--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today released its 2022 Sustainability Report highlighting accomplishments in environmental, social, and governance (ESG) across its global markets. The report details the Company’s efforts to optimize value while revolutionizing health outcomes and driving a sustainable future.
ZacksBellRing Brands (BRBR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
BellRing Brands (BRBR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksInsulet (PODD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Insulet (PODD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksThe Zacks Analyst Blog Highlights BioRad Laboratories, Henry Schein, Insulet, Abbott and LabCorp
BioRad Laboratories, Henry Schein, Insulet, Abbott and LabCorp are included in this Analyst Blog.
ZacksIllumina (ILMN) Q1 Earnings Beat Estimates, Margins Contract
Illumina's (ILMN) Q1 revenues decline year over year, reflecting the impact of Covid-19 monitoring headwinds and the transition of its high-throughput customers to NovaSeq X.
- Zacks
3 MedTech Stocks Likely to Beat Estimates in Q1 Earnings
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how BIO, HSIC and PODD are poised ahead of their earnings releases.
Business WireInsulet Announces FDA Clearance of Omnipod GO™, a First-of-its-Kind Basal-Only Insulin Pod, Further Simplifying Life for People with Type 2 Diabetes
ACTON, Mass., April 25, 2023--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the FDA clearance of its latest innovation, Omnipod GO™, an insulin delivery device cleared for use for people with type 2 diabetes age 18 or older who would typically take daily injections of long-acting insulin.
ZacksWhy Insulet (PODD) is Poised to Beat Earnings Estimates Again
Insulet (PODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ZacksWant Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
ZacksMyriad Genetics (MYGN) Gets Permit to Expand Tumor Testing
Myriad Genetics (MYGN) and Intermountain Precision Genomics receive the New York State Clinical Laboratory Permit to offer solid tumor testing to patients in all 50 U.S. states.
ZacksInsulet's (PODD) New Omnipod, Strategic Moves Drive Growth
Insulet (PODD) has been progressing well with respect to its four-pillar strategy, where the first two pillars include expanding access and awareness and delivering consumer-focused innovation.
- Simply Wall St.
Market Participants Recognise Insulet Corporation's (NASDAQ:PODD) Revenues
Insulet Corporation's ( NASDAQ:PODD ) price-to-sales (or "P/S") ratio of 17.2x might make it look like a strong sell...
